Thomas Stank, MD
Ophthalmology · Jonesboro, ARNPI 1598779209
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,600 of the $16,055 with a category attached, or 66.0%. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 69.6% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $11,526 and has fallen 94.0% since, to $691 in 2025. Among ophthalmology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $74.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$11K
- AbbVie$2K
- Sight Sciences, Inc.$519
- Biotissue Holdings Inc.$430
- Mallinckrodt Hospital Products Inc.$405
- Alcon$353
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$10,60066%
- Travel & lodging$1871%
- Food & beverage$5,16332%
- Entertainment$1051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $11,167 |
| AbbVie(2 entities) | 68 | $1,626 |
| Sight Sciences, Inc. | 12 | $519 |
| Biotissue Holdings Inc. | 7 | $430 |
| Mallinckrodt Hospital Products Inc. | 11 | $405 |
| Alcon | 16 | $353 |
| Bausch & Lomb Americas Inc. | 13 | $250 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $200 |
| Novartis | 10 | $169 |
| Optos, Inc. | 4 | $153 |
| Oyster Point Pharma, Inc. | 7 | $127 |
| Amgen(2 entities) | 6 | $111 |
| Shire North American Group Inc | 6 | $81 |
| Ivantis, Inc | 3 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Rayner Intraocular Lenses Limited | 3 | $51 |
| Glaukos Corporation | 3 | $46 |
| Eyepoint US, Inc. | 2 | $28 |
| Kala Pharmaceuticals, Inc. | 2 | $26 |
| Carl Zeiss Meditec USA, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $22 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Rxsight Inc | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $15 |
| Omeros Corporation | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$10,857
- DURYSTA$328
- PANORAMIC OPHTHALMOSCOPE$211
- OCT OPHTHALMOSCOPE$211
- NFC-700$105
How this compares
$16,055 in reported general payments places this provider in the 95th percentile of 125 ophthalmology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 612 | $30,374 |
| RestasisCyclosporine | 16 | $17,330 |
| XiidraLifitegrast | 19 | $17,040 |
| VyzultaLatanoprostene Bunod | 34 | $14,758 |
| LumiganBimatoprost | 38 | $11,552 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $9,325 |
| Latanoprost | 794 | $8,181 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $7,884 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 441 | $7,648 |
| Alphagan PBrimonidine Tartrate | 16 | $7,122 |
| Travoprost | 31 | $3,388 |
| Atropine Sulfate | 77 | $3,112 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $2,773 |
| Acetazolamide ErAcetazolamide | 26 | $1,633 |
| Pilocarpine Hcl | 30 | $1,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,626 | $43,887104 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $250 | $31,79953 claims |
| AlconSimbrinza | $353 | $9,32539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 125 ophthalmology providers in Arkansas.
Other ophthalmology in Jonesboro
- Matthew MargolisJonesboro$17K
- Joshua LittleJonesboro$4K
- Daniel SinesRogers$81K
- Mike McFarlandPine Bluff$63K
- Jennifer DoyleLittle Rock$38K
- James LinderMarion$18K
- Andrew PerinNorth Little Rock$4K
- Jeffrey HoltHot Springs$4K
- Jonathan CascianoLittle Rock$4K
- Christian HesterLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.